PR NEWSWIRE - Contenuti promozionali

immediapress comunicato stampa

Ribo Submits European Clinical Trial Application for a Novel Dual Targeting siRNA SR122 for Mixed and Severe Dyslipidemia, Further Strengthening Its Footprint in the Area of Lipid Disorder

SUZHOU, China and MÖLNDAL, Sweden, Nov. 10, 2026 /PRNewswire/ -- Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the submission of a Phase Ⅰ Clinical Trial Application (CTA) in EU for SR122, a dual GalNAc conjugated siR...



SEGUICI SUI SOCIAL

threads whatsapp linkedin twitter youtube facebook instagram

ora in
Prima pagina
articoli
in Evidenza